Evaluation of the Effect of Telmisartan (Micardis 80 mg/ MicardisPlus 80/12.5 mg; 80/25 mg) on Blood Pressure and Cardiovascular Risk Factor Index in High Risk Hypertensive Patients.
Phase of Trial: Phase IV
Latest Information Update: 02 Jun 2014
At a glance
- Drugs Telmisartan (Primary) ; Telmisartan/hydrochlorothiazide (Primary)
- Indications Cardiovascular disorders; Hypertension
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 07 Apr 2011 Actual end date (1 Jan 2011) added as reported by ClinicalTrials.gov.
- 07 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.